Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease
about
Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 InhibitorsLarge-scale transcriptome sequencing and gene analyses in the crab-eating macaque (Macaca fascicularis) for biomedical researchRole of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury.New strategies for targeting matrix metalloproteinasesMatrix metalloproteinase inhibition by heterotrimeric triple-helical Peptide transition state analoguesSynthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitorsMonitoring and Inhibiting MT1-MMP during Cancer Initiation and Progression.Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study.Synthesis, Biological Evaluation, and Docking of Dihydropyrazole Sulfonamide Containing 2-hydroxyphenyl Moiety: A Series of Novel MMP-2 Inhibitors.Progress towards water-soluble triazole-based selective MMP-2 inhibitors.An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.Altered Expression of Matrix Metalloproteinases and Their Endogenous Inhibitors in a Human Isogenic Stem Cell Model of Huntington's Disease.Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.
P2860
Q27715081-2EED53FB-FE7E-452D-9942-702DDED8331FQ28713670-D59AA088-DB20-481E-B431-4985A40113AFQ34801330-DADE7C63-1D68-4932-90EF-26AB19C73BC3Q35544060-C7DB388B-3100-4372-B08C-22A1A5E568C2Q35557168-681793D1-478D-4C5C-B816-C20435728ACFQ35871254-4AFA2FE8-9892-4D8F-A3B7-F6A94E61F0D8Q37693503-1D1BE248-FE7E-405B-AD04-86472678423EQ38461606-2AABCC61-2610-478C-B07F-232EE509EB0CQ38755272-76DA8E06-F464-4AB7-8F19-17B5048977ABQ38865435-A5C3F2E6-D8F9-4292-8693-2AF6249260FFQ39103154-1CB94FED-5C2C-4344-A9C7-11AD4394DDB5Q39267210-9D94D308-F8B2-4744-8565-4D60591BA421Q39443765-6C4D0045-E45B-45C8-B432-383CCEB1D4A8Q49829727-A7B439AD-D074-4FFF-966B-B6954A0E6D61Q51088787-59E6362B-3D07-4280-ABC7-92CE30E856A1
P2860
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Orally active MMP-1 sparing α- ...... is, and cardiovascular disease
@ast
Orally active MMP-1 sparing α- ...... is, and cardiovascular disease
@en
Orally active MMP-1 sparing α- ...... is, and cardiovascular disease
@nl
type
label
Orally active MMP-1 sparing α- ...... is, and cardiovascular disease
@ast
Orally active MMP-1 sparing α- ...... is, and cardiovascular disease
@en
Orally active MMP-1 sparing α- ...... is, and cardiovascular disease
@nl
prefLabel
Orally active MMP-1 sparing α- ...... is, and cardiovascular disease
@ast
Orally active MMP-1 sparing α- ...... is, and cardiovascular disease
@en
Orally active MMP-1 sparing α- ...... is, and cardiovascular disease
@nl
P2093
P356
P1476
Orally active MMP-1 sparing α- ...... is, and cardiovascular disease
@en
P2093
Alan M Easton
Brian R Bond
Carol Pearcy Howard
Chris L Funckes-Shippy
Chris P Carron
Clara I Villamil
Craig A Swearingen
Daniel P Becker
Dean Welsch
Gary A Decrescenzo
P304
P356
10.1021/JM100669J
P407
P577
2010-09-01T00:00:00Z